New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
16:08 EDTBGMDBG Medicine obtains CE Mark and launches automated BGM Galectin-3 test
BG Medicine announced that the first automated version of the BGM Galectin-3 blood test has obtained a CE Mark, an important step in the company's commercial strategy. The BGM Galectin-3 test will be distributed through bioMérieux's VIDAS immunoassay platform which includes about 27,000 installed instruments worldwide. bioMérieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMérieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
08:45 EDTBGMDBG Medicine sees requiring additional capital in 'near future'
Paul Sohmer, CEO of BG Medicine, said: "FDA clearance of the first automated assay for galectin-3 represents a significant commercial milestone for BG Medicine. Our commercial strategy will increasingly rely on the success of our automated partners to commercialize automated testing for galectin-3. We anticipate that beginning in the second half of 2015 our growth in revenues will depend on the timing and extent to which our automated partners are successful in gaining adoption of their automated tests for galectin-3. Concurrently, we will continue to manage aggressively our operating expenses and cash burn. We also expect that we will require additional capital in the near future to continue our operations and grow our business."
07:18 EDTBGMDBG Medicine files Premarket Notification with FDA for BGM Galectin-3 Test
Subscribe for More Information
07:11 EDTBGMDBG Medicine reports Q4 EPS (4c), one estimate (5c)
Reports Q4 revenue $554,000, one estimate $800,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use